(RTTNews) - Sandvik AB (SDVKF, SDVKY, SAND.ST), a Swedish engineering group, on Tuesday reported net income declined despite higher revenue in the fourth quarter compared with the previous year and proposed a higher dividend for 2025. For the fourth quarter, profit attributable to owners of the parent company decreased 2 percent to SEK 4.20 billion from SEK 4.30 billion in the prior year. Earnings...
(RTTNews) - Sandvik AB (SDVKF, SDVKY, SAND.ST), a Swedish engineering group, on Tuesday reported net income declined despite higher revenue in the fourth quarter compared with the previous year and proposed a higher dividend for 2025. For the fourth quarter, profit attributable to owners of the parent company decreased 2 percent to SEK 4.20 billion from SEK 4.30 billion in the prior year. Earnings per share SEK 3.35 versus SEK 3.42 last year. Adjusted earnings per share were SEK 3.38 versus SEK 3.25 last year. On average, six analysts had expected the company to report SEK 3.43 per share. Analysts' estimates typically exclude special items. Adjusted EBITDA rose 1 percent to SEK 6.37 billion from SEK 6.29 billion in the previous year. Operating profit increased to SEK 5.89 billion from SEK 5.75 billion in the prior year. Revenue increased to SEK 32.46 billion from SEK 32.15 billion in the previous year. Further, the board has proposed a dividend of SEK 6 per share for 2025, up from SEK 5.75 a year earlier. The proposed dividend corresponds to a total payout of SEK 7.53 billion, compared with SEK 7.21 billion in the previous year. The proposed record date for the dividend is April 30. The dividend is expected to be paid on May 6. On Monday, Sandvik closed trading 1.77% higher at SEK 339 on the Stockholm Stock Exchange. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
South Africa’s government will offer companies new incentives in an initiative to capitalize a fund that will be used to promote Black economic empowerment, Business Day reported, citing a Ministry of Trade, Industry and Competition document. Under the proposal, companies that contribute 3% of their net income to a so-called Transformation Fund will earn double the points currently available for a...
South Africa’s government will offer companies new incentives in an initiative to capitalize a fund that will be used to promote Black economic empowerment, Business Day reported, citing a Ministry of Trade, Industry and Competition document. Under the proposal, companies that contribute 3% of their net income to a so-called Transformation Fund will earn double the points currently available for a scorecard that measures businesses’ support for greater economic inclusion, the Johannesburg-based newspaper said. The increased number of points will improve companies’ access to government and corporate procurement. The fund will be governed by a board appointed by the minister and supported by a public-private investment committee, the paper said. The revamped proposals are expected to be unveiled next week, it said. S. Africa Mulls Transformation Levy on Unlisted Firms, BD Says No. 2 South African Party Slams $5.4 Billion Black-Fund Plan South Africa President Confirms 100b-Rand Transformation Fund
The future looks bright for this high-flying biotech stock. Mirum Pharmaceuticals' (MIRM +2.79%) share price has more than doubled over the last 12 months. Is this biotech stock about to soar again in 2026? I think so – for two key reasons. At an inflection point In several important ways, Mirum is at an inflection point. It achieved positive cash flow from operations in 2025. That's a significant...
The future looks bright for this high-flying biotech stock. Mirum Pharmaceuticals' (MIRM +2.79%) share price has more than doubled over the last 12 months. Is this biotech stock about to soar again in 2026? I think so – for two key reasons. At an inflection point In several important ways, Mirum is at an inflection point. It achieved positive cash flow from operations in 2025. That's a significant milestone for any small biotech company. Expand NASDAQ : MIRM Mirum Pharmaceuticals Today's Change ( 2.79 %) $ 2.63 Current Price $ 96.92 Key Data Points Market Cap $5.0B Day's Range $ 93.23 - $ 98.49 52wk Range $ 36.88 - $ 98.49 Volume 882K Avg Vol 738K Gross Margin 79.85 % Mirum won two approvals from the U.S. Food and Drug Administration (FDA) last year. In February, the agency gave Ctexli a thumbs-up for the treatment of cerebrotendinous xanthomatosis (CTX), a rare genetic disorder of bile acid synthesis. The FDA also approved a tablet formulation of Livmarli in April for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC), both rare liver diseases. On Jan. 26, 2026, Mirum completed the acquisition of Bluejay Therapeutics. This transaction adds brelovitug to Mirum's pipeline. Brelovitug is a promising therapy targeting chronic hepatitis delta virus (HDV), a rare liver disease with no approved treatment in the U.S. Net product sales for Livmarli jumped 69% year over year in 2025 to $359 million. Sales for bile acid replacement therapies Cholbam and Ctexli increased 31% year over year to $161 million. Mirum also expects solid momentum this year, with overall revenue guidance of $630 million to $650 million. Multiple potential catalysts ahead 2026 should also be loaded with catalysts for Mirum. The most important one, in my view, is the company's anticipated announcement in the second quarter of results from a Phase 2B clinical study evaluating volixibat for the treatment of primary scler...